NCT02334306: A reported trial by MedImmune LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02334306 |
|---|---|
| Title | A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 8, 2015 |
| Completion date | Jan. 16, 2018 |
| Required reporting date | Jan. 16, 2019, midnight |
| Actual reporting date | Jan. 16, 2019 |
| Date last checked at ClinicalTrials.gov | Oct. 31, 2025 |
| Days late | None |